3-MeO-PCE

3-Methoxyeticyclidine (3-MeO-PCE), also known as methoxieticyclidine,[1] is a dissociative anesthetic that is qualitatively similar to PCE and PCP[1] and has been sold online as a designer drug.[2][3][4]

3-MeO-PCE
3-MeO-PCE.svg
Clinical data
Other names3-MeO-PCE; Methoxieticyclidine
Legal status
Legal status
Identifiers
  • N-Ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H23NO
Molar mass233.355 g·mol−1
3D model (JSmol)
  • CCNC1(CCCCC1)C2=CC(=CC=C2)OC
  • InChI=1S/C15H23NO/c1-3-16-15(10-5-4-6-11-15)13-8-7-9-14(12-13)17-2/h7-9,12,16H,3-6,10-11H2,1-2H3
  • Key:OFGOOZLOGUNDFS-UHFFFAOYSA-N

On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of methoxetamine should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCE.[5]

This report also described the receptor binding profile of methoxetamine and three additional dissociatives 3-MeO-PCP, 4-MeO-PCP, and 3-MeO-PCE, showing them to have significant affinity for the PCP site of the NMDA receptor (NMDAR) and was later published in more detail.[6]

3-MeO-PCE has Ki values of 61 nM for the NMDAR, 743 nM for the dopamine transporter, 2097 nM for the histamine H2 receptor, 964 nM for the alpha-2A adrenergic receptor, 115 nM for the serotonin transporter, 4519 nM for the σ1 receptor, and 525 nM for the σ2 receptor.[6]

Legal statusEdit

3-MeO-PCE is banned in Sweden[7][8] and Switzerland.[9]

See alsoEdit

ReferencesEdit

  1. ^ a b Morris H, Wallach J (July–August 2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID 24678061.
  2. ^ De Paoli G, Brandt SD, Wallach J, Archer RP, Pounder DJ (June 2013). "From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices". Journal of Analytical Toxicology. 37 (5): 277–83. doi:10.1093/jat/bkt023. PMID 23552616.
  3. ^ Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, et al. (August 2016). "Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines" (PDF). Drug Testing and Analysis. 8 (8): 801–15. doi:10.1002/dta.1861. PMID 26360516.
  4. ^ "3-MeO-PCE". New Synthetic Drugs Database. Archived from the original on 2016-07-29. Retrieved 2016-08-27.
  5. ^ "Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012". UK Home Office. 18 October 2012.
  6. ^ a b Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (March 2013). "The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor". PLOS ONE. 8 (3): e59334. Bibcode:2013PLoSO...859334R. doi:10.1371/journal.pone.0059334. PMC 3602154. PMID 23527166.
  7. ^ "Elva nya ämnen klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 28 June 2018.
  8. ^ Riksdagsförvaltningen. "Förordning (1992:1554) om kontroll av narkotika". riksdagen.se (in Swedish).
  9. ^ "Verordnung des EDI vom 30. Mai 2011 über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI)" (in German). Der Bundesrat.